Skip to content

Massimiliano Magnelli's lobbying: the registrations they file and every meeting they've reported since November 2021.

← Lobbying

Registrant (responsible officer)

Massimiliano Magnelli

President and General Manager

For companies and organizations, the most senior paid officer files the registration and the monthly reports, whoever attended the meeting.

Meetings this Parliament
5
Since Nov 2021
5
Active registrations
1

Registered for

Reported meetings

  • Bristol Myers Squibb Canada
    • Nicholas Chesterley · Director General, Finance Canada (FIN)
    • Nyssa McLeod · Director, Finance Canada (FIN)

    C-6444-1

    Bill C-64 (Pharmacare Act - 2024) Patented Medicine Prices Review Board (PMPRB) Reform Most Favored Nation National Pharmacare Drugs for Rare Diseases

    Official report

  • Bristol Myers Squibb Canada
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)

    C-6444-1

    Bill C-64 (Pharmacare Act - 2024) Patented Medicine Prices Review Board (PMPRB) Reform Most Favored Nation National Pharmacare Drugs for Rare Diseases

    Official report

  • Bristol Myers Squibb Canada
    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Mark Schaan · Associate Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Kaili Levesque · Associate Deputy Minister, Federal Economic Development Agency for Southern Ontario (FedDev)

    C-6444-1

    Bill C-64 (Pharmacare Act - 2024) Patented Medicine Prices Review Board (PMPRB) Reform Most Favored Nation National Pharmacare Drugs for Rare Diseases

    Official report

  • Bristol Myers Squibb Canada
    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)

    C-6444-1

    Bill C-64 (Pharmacare Act - 2024) Patented Medicine Prices Review Board (PMPRB) Reform Most Favored Nation National Pharmacare Drugs for Rare Diseases

    Official report

  • Bristol Myers Squibb Canada
    • Justine Frame · Policy Advisor, Health Canada (HC)

    C-6444-1

    Bill C-64 (Pharmacare Act - 2024) Patented Medicine Prices Review Board (PMPRB) Reform Most Favored Nation National Pharmacare Drugs for Rare Diseases

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.